HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Stefan Bittner Selected Research

Potassium Channels (Potassium Channel)

5/2015The two-pore domain potassium channel KCNK5 deteriorates outcome in ischemic neurodegeneration.
1/2015Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms.
10/20134-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.
1/2013Correction: Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9).
12/2012The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis.
1/2011Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients.
7/2010Upregulation of K2P5.1 potassium channels in multiple sclerosis.
1/2010Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9).
9/2009TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system.
12/2008Altered neuronal expression of TASK1 and TASK3 potassium channels in rodent and human autoimmune CNS inflammation.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Stefan Bittner Research Topics

Disease

11Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
01/2015 - 01/2008
11Multiple Sclerosis
01/2015 - 01/2008
7Inflammation
08/2014 - 12/2008
5Stroke (Strokes)
05/2015 - 01/2009
3Relapsing-Remitting Multiple Sclerosis
01/2015 - 04/2010
3Brain Ischemia (Cerebral Ischemia)
01/2013 - 01/2010
2Rheumatoid Arthritis
01/2015 - 01/2011
2Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
06/2014 - 01/2009
2Encephalitis (Encephalitis, Rasmussen)
07/2013 - 01/2013
1Polymyositis
03/2015
1Brain Injuries (Brain Injury)
11/2014
1Graft vs Host Disease (Graft-Versus-Host Disease)
08/2014
1Demyelinating Diseases (Demyelinating Disease)
10/2013
1Neoplasms (Cancer)
09/2013
1Herpes Zoster
09/2013
1Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
09/2013
1Ischemia
01/2013
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2012
1Paralysis (Palsy)
03/2011
1Weight Loss (Weight Reduction)
03/2011
1Central Nervous System Diseases (CNS Diseases)
12/2010
1Glioma (Gliomas)
05/2008

Drug/Important Bio-Agent (IBA)

11Potassium Channels (Potassium Channel)IBA
05/2015 - 05/2008
4oligodendrocyte-myelin glycoproteinIBA
01/2014 - 02/2010
2alemtuzumab (Campath)FDA Link
03/2015 - 01/2015
2natalizumab (Tysabri)FDA Link
07/2013 - 02/2011
2Glutamic Acid (Glutamate)FDA Link
01/2013 - 01/2008
1Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric
11/2014
1NAADP (nicotinic acid adenine dinucleotide phosphate)IBA
11/2014
14-amylcinnamoylanthranilic acidIBA
11/2014
1Adenosine Diphosphate Ribose (ADP-Ribose)IBA
11/2014
1HLA-G antigen (HLA G)IBA
08/2014
1phospholipase D1IBA
08/2014
1tebufenozide (Mimic)IBA
07/2014
1copolymer 1 (glatiramer acetate)FDA Link
07/2014
1Integrin alpha4beta1 (VLA-4)IBA
06/2014
1AntibodiesIBA
06/2014
14-Aminopyridine (4 Aminopyridine)IBA
10/2013
1bisindolylmaleimideIBA
09/2013
1Protein Kinases (Protein Kinase)IBA
09/2013
1claudin 3IBA
09/2013
1Linseed Oil (Flaxseed Oil)IBA
09/2013
1RiluzoleFDA LinkGeneric
09/2013
1alpha-Linolenic Acid (Linolenic Acid)IBA
09/2013
1AntigensIBA
01/2013
1hyperpolarization-activated cation channelIBA
01/2013
1PotassiumIBA
01/2013
1Antigen-Antibody Complex (Immune Complex)IBA
01/2013
1rituximab (Mabthera)FDA Link
01/2013
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2013
1Interleukin-17 (Interleukin 27)IBA
01/2012
1Ion Channels (Ion Channel)IBA
12/2011
1myelin oligodendrocyte glycoprotein (35-55)IBA
03/2011
1Bradykinin Receptors (Bradykinin Receptor)IBA
03/2011
1Nerve Growth Factors (Neurotrophins)IBA
12/2010
1CytokinesIBA
12/2010
1Transforming Growth Factor beta (TGF-beta)IBA
04/2010
1Transcription Factors (Transcription Factor)IBA
04/2010
1anandamide (arachidonylethanolamide)IBA
01/2009
1OxygenIBA
01/2009
1Tandem Pore Domain Potassium Channels (Tandem Pore Domain Potassium Channel)IBA
01/2009
1IsofluraneFDA LinkGeneric
05/2008
1tranilast (N 5')IBA
05/2008
1Messenger RNA (mRNA)IBA
05/2008
1Excitatory Amino AcidsIBA
01/2008

Therapy/Procedure

1Therapeutics
10/2010
1Immunotherapy
06/2009